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Mitochondrial Phosphate–Carrier Deﬁciency: A Novel Disorder
of Oxidative Phosphorylation
Johannes A. Mayr, Olaf Merkel,* Sepp D. Kohlwein, Boris R. Gebhardt, Hansjosef Bo¨hles,
Ulrike Fo¨tschl, Johannes Koch, Michaela Jaksch,† Hanns Lochmu¨ller, Rita Horva´th,
Peter Freisinger, and Wolfgang Sperl
The mitochondrial phosphate carrier SLC25A3 transports inorganic phosphate into the mitochondrial matrix, which is
essential for the aerobic synthesis of adenosine triphosphate (ATP). We identiﬁed a homozygous mutation—c.215GrA
(p.Gly72Glu)—in the alternatively spliced exon 3A of this enzyme in two siblings with lactic acidosis, hypertrophic
cardiomyopathy, and muscular hypotonia who died within the 1st year of life. Functional investigation of intact mi-
tochondria showed a deﬁciency of ATP synthesis in muscle but not in ﬁbroblasts, which correlated with the tissue-
speciﬁc expression of exon 3A in muscle versus exon 3B in ﬁbroblasts. The enzyme defect was conﬁrmed by comple-
mentation analysis in yeast. This is the ﬁrst report of patients with mitochondrial phosphate–carrier deﬁciency.
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Defects in oxidative phosphorylation are a frequent cause
of a disturbed mitochondrial energy metabolism and oc-
cur with a prevalence of at least 1 in 7,600.1 The clinical
spectrum of this group of diseases is heterogeneous, with
variable onset and course ranging from neonatal onset
with early death to adult forms with milder clinical affec-
tion. Multiple organ involvement is frequently observed,
but tissue-speciﬁc variants are also known. The broad clin-
ical spectrum is mirrored at the molecular level by possible
defects of 1100 different proteins and genes of the nuclear
and mitochondrial genome, complicating the diagnosis of
these diseases at the molecular level.
The respiratory-chain enzymes I, III, and IV create a pro-
ton gradient across the inner mitochondrial membrane
during their oxidative reaction. This proton gradient is
used for the production of adenosine triphosphate (ATP)
and various transport processes (ﬁg. 1). ATP is synthesized
on the matrix side of the inner mitochondrial membrane
from adenosine diphosphate (ADP) and inorganic phos-
phate by F1F0-ATP synthase. Import of inorganic phos-
phate into the mitochondrial matrix is an energy-depen-
dent, oriented process that is catalyzed by the mitochon-
drial phosphate–carrier protein (PiC) termed “SLC25A3,”
a member of the mitochondrial-carrier family. Mitochon-
drial carriers facilitate the transport of a variety of sub-
stances across the inner mitochondrial membrane. They
are characterized by a common structure that includes six
transmembrane helices, and they share conserved motifs
in their primary sequence.2
Mitochondrial PiC is an essential part of the mitochon-
drial energy–producing machinery. Evidence comes from
studies with yeast, a facultative anaerobe organism with
dispensable oxidative phosphorylation on fermentable car-
bon sources (e.g., glucose). Absence of both isoforms of
mitochondrial PiC, encoded by the MIR1 and PIC2 genes,
renders cells viable on glucose but unable to grow on non-
fermentable carbon sources.3 In mammals, mitochondrial
PiC is ubiquitously expressed but is found in two distinct
isoforms, termed “PiC-A” and “PiC-B.” These two isoforms
originate from alternatively spliced transcripts that differ
in a mutually exclusive exon; exon 3A has tissue-speciﬁc
expression in heart and muscle, whereas exon 3B is the
predominant isoform in other tissues.3,4 The alternatively
spliced exons code for 42 and 41 aa in isoforms A and B,
respectively, and are 170% identical. In vitro, the two iso-
forms display different substrate afﬁnities and transport
rates.5
Here, we describe two patients from a single family who
had a cardiac and muscular disease and a tissue-speciﬁc
defect in the mitochondrial PiC. Patient 1, a girl, the sec-
ond child of nonconsanguineous Turkish parents, was born
after an uneventful pregnancy in the 38th wk of gestation,
with a birth weight of 2,600 g (10th–50th percentile),
length of 47 cm (10th–50th percentile), head circumfer-
ence of 33 cm (10th–50th percentile), and Apgar scores
of 9, 10, and 10 (at ages 1, 5, and 10 min, respectively).
At age 12 h, the child presented with cyanosis and muscu-
lar hypotonia that necessitated intensive-care treatment.
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Figure 1. Functional elements of mitochondrial ATP synthesis.
Inorganic phosphate (Pi) is transported into the mitochondrial
matrix by the mitochondrial PiC. F1F0-ATP synthase forms ATP from
Pi and ADP. ATP is exchanged across the inner mitochondrial mem-
brane with ADP by the ANT. The whole reaction is driven by a
proton gradient, which is maintained mainly by the respiratory-
chain (RC) complexes I, III, and IV. CCCP is an artiﬁcial proton
pore that destroys the proton gradient across the mitochondrial
inner membrane. In the presence of CCCP, the RC is maximally
stimulated, but no ATP is formed.
Figure 2. Respiratory-chain activity stimulated by CCCP, exclud-
ing ATP synthesis, in relation to oxidative phosphorylation stim-
ulated by ADP, including the synthesis of ATP. This ratio is shown
in muscle of patient 1 (P1) (blackened triangle), in 31 control
individuals (unblackened triangles) (mean 1.01, SD 0.09), in ﬁbro-
blasts of patient 1 and patient 2 (P2) (blackened circles), and in
18 controls (unblackened circles) (mean 1.01, SD 0.15).
Echocardiography revealed a hypertrophic cardiomyopa-
thy with low cardiac output. Laboratory investigations of
blood carnitine, acyl-carnitines, amino acids, and organic
acids in urine revealed no speciﬁc abnormalities. Lactate
was constantly elevated in plasma, at 4–13 mmol/liter.
With anticongestive therapy, the patient stabilized clini-
cally, but cardiac hypertrophy was progressive. Severe mus-
cular hypotonia and failure to thrive persisted. She had a
poor weight gain despite high caloric intake. At age 4 mo,
she died from heart failure. Muscle biopsy had been per-
formed at age 2 wk. Histological examination showed lipid
myopathy with lipid accumulation in both ﬁber types,
prominent in type I ﬁbers. There were no ragged red ﬁ-
bers on Gomori trichrome stain, but the oxidative enzyme
stains nicotinamide adenine dinucleotide dehydrogen-
ase, succinate dehydrogenase, and cytochrome c oxidase
showed an abnormal mitochondrial network without rel-
evant mitochondrial proliferation. Both lipid accumula-
tion and the mitochondrial changes were conﬁrmed by
electron microscopy.
Patient 2, the elder sister of patient 1, was born at term,
with a birth weight of 2,870 g (10th percentile), length of
53 cm (50th–90th percentile), head circumference of 33
cm (10th percentile), and Apgar scores of 8, 10, and 10
(at ages 1, 5, and 10 min, respectively). At age 10 h, she
presented with muscular hypotonia, respiratory distress,
metabolic acidosis (pH 6.9), and lactic acidosis (17 mmol/
liter) that necessitated intensive-care treatment. Artiﬁcial
ventilation was necessary for a period of 3 mo. The girl
developed increasing hypertrophic cardiomyopathy. Met-
abolic workup revealed constantly elevated plasma lactate
(5–14 mmol/liter) and an increased lactate:pyruvate ratio
of 62. Blood carnitine, acyl-carnitines, amino acids, and
organic acids in urine were normal. During her life, the
child presented with severe muscular hypotonia and re-
current episodes of respiratory insufﬁciency that neces-
sitated artiﬁcial ventilation. At age 9 mo, the child died
from intractable low-output hypertrophic heart failure.
Muscle biopsy had been performed at age 2 wk. No ab-
normalities were found via light microscopy. Electron mi-
croscopy revealed atypical and enlarged mitochondria, as
well as an increased amount of lipid droplets indicative
of a defect in fatty-acid oxidation ormitochondrial-energy
metabolism. However, investigation of respiratory-chain
enzymes showed no signiﬁcant abnormalities. Activities
in U/g protein (normal range) were as follows: for com-
plex I, 20 (12–40); for complex IIIII, 11 (6–25); for cy-
tochrome c oxidase, 81 (90–281); and for citrate synthase,
79 (45–105).
Investigation of intact mitochondria-enriched postnu-
clear supernatant from a fresh muscle biopsy specimen of
patient 1 showed a severely reduced state 3 respiration of
pyruvate, malate, and succinate (table 1).6 In the presence
of the uncoupler CCCP (carbonyl cyanide m-chlorophen-
ylhydrazone), a normal respiration rate was achieved (ta-
ble 1 and ﬁg. 2). This result was clear evidence of a de-
fective synthesis of ATP in muscle. However, normal func-
tion of the respiratory chain (uncoupled oxidation) re-
mained. As for patient 2, for patient 1, activity of respi-
ratory-chain enzymes7 and pyruvate dehydrogenase8 was
also normal, as was the oligomycin-sensitive ATPase of
complex V7 (table 1). Analysis of pyruvate oxidation in
digitonin-permeabilized ﬁbroblasts showed normal ratios
of CCCP versus ADP stimulated in both patients, conclu-
sive for a normal ATP synthesis in ﬁbroblasts in contrast
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Table 1. Functional and Enzymatic Investigations of
Muscle Tissue
Biochemical Measurements Patient 1 Controls
Substrate oxidation rate (nmol/h/mg protein):
[1–14C]pyruvatemalateADP 45 263–900
[1–14C]pyruvatecarnitineADP 98 302–856







Enzyme activity (unit/g protein):
Citrate synthase 196 150–325
Complex I 63 28–76
Complex IIII 136 64–218
Complex II 80 39–102
Complex IIIII 108 93–180
Complex III 622 426–762
Cytochrome c oxidase 539 452–889
Oligomycin-sensitive ATPase (complex V) 137 70–397
Pyruvate dehydrogenase 7.2 6.1–19.8
NOTE.—Postnuclear supernatant prepared from native, unfrozen muscle showed re-
duced activities in all ADP-stimulated oxidation reactions but was normal in the
presence of the uncoupler CCCP. Analysis of respiratory-chain enzymes, ATPase, and
pyruvate dehydrogenase revealed normal activities.
to muscle (ﬁg. 2). This was in accordance with the clinical
presentation of cardiomyopathy and muscular hypotonia
that was indicative of a tissue speciﬁcity of the defect.
Defective mitochondrial ATP synthesis (ﬁg. 1) can be
attributed to deﬁciencies of the F1F0-ATP synthase, the ad-
enine nucleotide translocator (ANT), or themitochondrial
phosphate carrier. A possible defect of the F1F0-ATP syn-
thase was ruled out by (1) normal oligomycin-sensitive
ATPase activity, (2) normal levels of the enzyme on Blue
Native polyarcylamide gels, and (3) sequence analysis of
the ATP6 and ATP8 genes of ATP synthase subunits en-
coded by the mtDNA, which showed no pathogenic mu-
tations. These investigations excluded all known presen-
tations of ATP-synthase disorders. The search for muta-
tions was next focused on the ANT whose isoforms are
known to be expressed in a tissue-speciﬁc manner. The
isoform encoded by the SLC25A4 (formerly known as
“ANT1”) gene that is expressed in heart and muscle was
sequenced,9 but no mutation could be detected.
Finally, we investigated the mitochondrial phosphate
carrier gene SLC25A3, located on chromosome 12q23.1.
PCR ampliﬁcation of the eight exons was performed with
the following set of primers that started from the ﬂanking
intron or the noncoding parts of exon 1 or 8, respectively:
for exons 12, 5′-ACACATCTTAGGACCCGGAG-3′ (for-
ward) and 5′-ACTCGTCCTTCCCTGTCCT-3′ (reverse), with
a product of 578 bp; for exon 3, 5′-TTCTTTCATTCCAGTG-
GCCT-3′ (forward) and 5′-CTAGCAGTTGTGATGTCTTC-
AAA-3′ (reverse), with a product of 583 bp; for exon 4, 5′-
TATGTTAGCTGTTTGGTGCA-3′ (forward) and 5′-GGAAC-
TACGCAAAGGAGTCC-3′ (reverse), with a product of 526
bp; for exon 5, 5′-GGACTCCTTTGCGTAGTTCC-3′ (for-
ward) and 5′-GTGACAGAGCGAGACTTTGT-3′ (reverse),
with a product of 506 bp; for exon 6, 5′-GTGTGCGGACA-
TTTCTGTTA-3′ (forward) and 5′-AAAAAACGCCAATAAT-
GGAA-3′ (reverse), with a product of 327 bp; and, for exons
78, 5′-TGGCTCTGTGAAGTTTTGTT-3′ (forward) and 5′-
TCCTTTTGCACTTTCTTCAA-3′ (reverse), with a product
of 481 bp. An annealing temperature of 54C was used for
all reactions. PCRs generating products !2,000 bp were
performed with RedHot DNA polymerase (ABgene [HVD
Life Sciences]). PCRs generating larger products and the
cloning reactions were performed with AccuTaq DNA poly-
merase (Sigma-Aldrich), according to the manufacturer’s
protocol. Sequencing (CEQ-8000 [Beckman Coulter]) re-
vealed a homozygous missense mutation, c.215GrA (ﬁg.
3), resulting in the substitution p.Gly72Glu in the two
patients (GenBank accession number NM_005888). The
parents are heterozygous carriers. The mutation was ver-
iﬁed by restriction analysis (ﬁg. 3). This mutation was not
detectable in 376 chromosomes of Turkish control indi-
viduals. Remarkably, this mutation is localized in exon 3A,
which is the alternatively spliced variant that produces
the heart/muscle–speciﬁc isoform of PiC. The affected
amino acid is located within the ﬁrst transmembrane he-
lix, and the substitution replaces a highly polar glutamic
acid in lieu of the small neutral amino acid glycine. Align-
ment of PiC proteins from other eukaryotic organisms (ﬁg.
4), performed with the ClustalW program,10 shows an ab-
solute interspecies conservation of glycine at this position.
Furthermore, this glycine of the ﬁrst transmembrane helix
is conserved in most other members of the mitochondrial
carrier family11 (ﬁg. 4), which consists of at least 46 mem-
bers in humans,12 responsible for various carrier functions.
The presence of this mutation in exon 3A prompted us
to investigate the tissue-speciﬁc expression of the two dif-
ferent isoforms of PiC in ﬁbroblasts, myoblasts, and mus-
cle (ﬁg. 5). Isoform B was predominant in ﬁbroblasts and
also in undifferentiated myoblasts. After changing the cul-
ture medium to a differentiation medium (Promocell) for
10 d, a clear shift from isoform B to isoform A could be
observed in differentiating myoblasts. Isoform A was pre-
sent predominantly in muscle tissue, both in healthy con-
trol tissue and in tissue of patient 1 of our study. In all
investigated muscle tissues, a small proportion of isoform
B was detectable that may originate from either myoblasts
or contaminating connective tissue or blood.
To test the functional relevance of the identiﬁed mu-
tation, we generated a strain of the yeast Saccharomyces
cerevisiae that is devoid of mitochondrial PiC activity. As
shown by Hamel and colleagues,3 S. cerevisiae has two dis-
tinct PiCs encoded by the MIR1 and PIC2 genes. Double
mutants were created by crossing the respective deletion
strains of the Euroscarf strain collection (Institute of Mi-
crobiology, Johann Wolfgang Goethe-University). The het-
erozygous diploids were sporulated, and the resulting col-
onies were tested by PCR analysis, to identify the double
mutants. Double mutants grew normally on glucose-con-
taining media but were unable to grow on 1% yeast ex-
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Figure 3. Sequence analysis (A) identiﬁed mutation c.215GrA resulting in the exchange p.Gly72Glu in exon 3A of the human
mitochondrial PiC gene SLC25A3. The mutation was also shown by RFLP analysis (B) with the PCR primers Exon3A, 5′-TTCTTTCATTCCAGTGG-
CCT-3′ (forward) and 5′-AAAACAAACCTGCATTCTGC-3′ (reverse), with a PCR product of 206 bp. Digestion with MnlI (Fermentas) resulted
in three fragments (119.5 bp, 58 bp, and 28.5 bp) for the normal allele and in two fragments (177.5 bp and 28.5 bp) in the mutated
allele. St p DNA ladder, low range (Fermentas).
Figure 4. Sequence alignment of the mitochondrial PiC from different organisms (upper) and other members of the mitochondrial
carrier (MC) family shows high conservation of the glycine 72 of human PiC isoform A. MRS3 p mitochondrial iron transporter; CTP1
p citrate transporter.
tract, 2% peptone, and the nonfermentable carbon source
glycerol (3%). Growth of the mir1-pic2 double mutant was
restored by transformation with the MIR1 wild-type gene
(plasmid YEp352-MIR1). TheMIR1 sequence that included
1,000 bp upstream and 500 bp downstream cloned into
the BamHI site of the episomal yeast plasmid after PCR
ampliﬁcation with BamHI site–tagged primersMIR1BamHI,
5′-CGGGATCCAAATATAAGCGTGCGCC-3′ (forward) and
5′-CGGGATCCAATGCAGAAGATGCGTCAAT-3′ (reverse),
with a 2,628-bp product. To clone the human PiC iso-
forms in a yeast-compatible vector system, the MIR1 ORF
in YEp352-MIR1 was replaced by an MluI site by PCR am-
pliﬁcation with primers tagged with Mlu I sites (under-
lined) mir1MluI, 5′-GGCACGCGTGGTCTTGATTGATAC-
ATGC-3′ (forward) and 5′-GGCACGCGTATGAGACTTTT-
TGATCTTTGTAGT-3′ (reverse), with a 6,871-bp product.
The PCR product was digested with MluI (Promega) and
was ligated (T4 Ligase [Promega]), and the resulting plas-
mid YEp352-Dmir1-MluI was used for cloning and sub-
sequent expression of the human PiC isoform A, as men-
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Figure 5. Investigation of mutually exclusive splicing of exons 3A and 3B of the human PiC in different tissues. DNA was ampliﬁed
by PCR from cDNA with the primers Ex2, 5′-CGCCGCCGTGGAAG-3′ (forward) and 5′-ACCACGAACACCATCCTCTT-3′ (reverse), starting from the
ﬂanking exons 2 and 4, respectively. The resulting products were digested with Tru9I (Fermentas), which resulted in fragments of 122
bp, 45 bp, 21 bp, and 22 bp for isoform A and in 92 bp, 72 bp, 21 bp, and 22 bp for isoform B, respectively. Lanes 1 and 2p control
ﬁbroblasts; lane 3p ﬁbroblasts from patient 1; lane 4p myoblasts, undifferentiated from patient 1; lane 5p myoblasts, differentiated
from patient 1; lane 6 p muscle from patient 1; lanes 7–10 p muscle from controls.
tioned below. The human PiC gene was cloned from cDNA
of muscle from either patient 1 or a control individual,
after PCR ampliﬁcation of the indicated coding regions
ﬂanked by MluI sites. The resulting clones were veriﬁed
by sequencing, to exclude any mutations that may have
been introduced by the cloning procedure.
The human PiC isoform A was cloned without the ﬁrst
49-aa targeting sequence that was shown to be not pro-
cessed by yeast13; this sequence was replaced by a methi-
onine codon. The cDNA was ampliﬁed with the following
set of primers tagged with MluI sites: hPIC49-MluI-F (5′-
GATACGCGTATGTTCTCGTCCGTGGCG-3′) and hPIC-
Mlu-R (5′-GGCACGCGTCTACTGAGTTAACCCAAGCTTT-
TTC-3′). The 959-bp product was cloned into the MluI site
of the YEp352-Dmir1-MluI plasmid, was transformed14 into
the yeast mir1-pic2 double mutant, and was selected for
growth on uracil-freemedium containing glucose (BIO101
[Eubio]). The transformed yeast mir1-pic2 double mutants
expressing the human wild-type PiC gene were able to
grow on glycerol medium, demonstrating functional com-
plementation by the heterologous PiC. However, the ef-
ﬁciency was rather low, resulting in an ∼10 times slower
growth rate compared with that of the YEp352-MIR1 plas-
mid harboring the authentic yeast carrier. No growth on
nonfermentable glycerol medium was found when mir1-
pic2 mutants were transformed with the mutant clone of
the human PiC prepared from patient 1 (ﬁg. 6), conﬁrm-
ing that the mutated PiC is nonfunctional.
Since the glycine residue that is mutated in the PiC of
our patients is conserved in yeast PiCs (ﬁg. 3), the cor-
responding glycine at position 24 in the yeast Mir1 pro-
tein was exchanged for a glutamic acid by site-speciﬁc
mutagenesis. The plasmid YEp352-MIR1 was PCR ampli-
ﬁed with mir-Nhe primers, 5′-TCGCgCTAGCCGaaGCC-
ATAG-3′ (forward) and 5′-TCGGCTAGcGCGAATTTCA-
TGTA-3′ (reverse) (changes from wild-type sequence in
lowercase letters), which introduced an NheI site (under-
lined) without changing theORF in addition to the desired
Gly24Glu mutation (GGCrGAA, in bold). The resulting
PCR product was digested with NheI (New England Bio-
labs), was ligated, was ampliﬁed, andwas transformed into
the yeast mir1-pic2 double mutant. The incorporated plas-
mid was analyzed by sequencing and showed the intro-
duced changes but no other mutations. As shown in ﬁgure
6, the resulting transformed yeast could not restore growth
on glycerol, demonstrating the functional relevance of the
mutation.
Taken together, the missense mutation c.215GrA
(p.Gly72Glu) found in our two patients affects a highly
conserved amino acid in the mitochondrial phosphate
carrier. The position is conserved in all known PiC se-
quences and, furthermore, in most other mitochondrial
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Figure 6. Expression of different PiC clones in the mutants of S. cerevisiae. Cells were grown for 3 wk on agarose plates containing
3% glycerol, 2% peptone, and 1% yeast extract. Segment 1 p wild-type strain BY4741; segment 2 p mir1-pic2 (mp) double mutant;
segment 3p mp hPICA-E (PiC-A from patient 1); segment 4p mp hPICA-G (PiC-A from a control individual); segment 5p mp yMIR1-
E (site-speciﬁc mutation of the S. cerevisiae gene); segment 6 p mp yMIR1-G (wild-type form of S. cerevisiae).
carrier proteins. The mutation introduces a large nega-
tively charged amino acid instead of a small glycine. Ex-
pression of the wild-type protein of human PiC isoform
A complemented the growth defect on glycerol of the
yeast mir1-pic2 strain, which was not possible within the
mutant form. Similarly, an exchange of the homologous
glycine for a glutamic acid in the yeast Mir1 protein dis-
abled growth complementation on the nonfermentable
glycerol medium.
This is, to our knowledge, the ﬁrst report of a disorder
in the synthesis of ATP due to amitochondrial phosphate–
carrier deﬁciency. So far, mutations in the other mitochon-
drial carrier involved in the ATP synthesis, the ANT, have
been reported. Most of the genetic defects of SLC25A4
(formerly ANT1) are heterozygous,15 but, recently, a ho-
mozygous mutation16 was identiﬁed. However, the path-
omechanism of the ANT defects identiﬁed so far seems to
be different from the phosphate–carrier deﬁciency de-
scribed here and to be due mainly to an interference with
the replication of the mtDNA. These patients are usually
healthy early in life and acquire more and more deleted
mtDNA. A high load of deletions of themtDNA eventually
results in a combined defect of the mitochondrially en-
coded enzymes of the oxidative phosphorylation. To prove
whether the mtDNA is deleted in our patients, the whole
mtDNA was ampliﬁed, in two distinct reactions, with the
following set of primers (at an annealing temperature of
58C): DLoop, 5′-CACCAGCCTAACCAGATTTCA-3′ (for-
ward) and 5′-TGGTMCCCAAATCTGCTTCC-3′ (reverse),
with a 15,679-bp product, as well as DLoop, 5′-CCAACCA-
AACCCCAAAGAC-3′ (forward) and 5′-TACTGCGACATA-
GGGTGCTC-3′ (reverse), with a 16,147-bp product. The
resulting product showed the normal full length but no
deleted mtDNA. Since mitochondrial PiC could inﬂuence
the nucleotide pool in mitochondria, we analyzedmtDNA
content in muscle of patient 1 but found no depletion.17
Therefore, no evidence of mtDNA changes due to mito-
chondrial PiC deﬁciency was detectable in our patients.
The main symptoms in our patients were cardiomyop-
athy, muscular hypotonia, and severe growth retardation
combined with lactic acidosis. Neurologic involvement
was not evident; however, brain magnetic resonance im-
aging was not performed for either of our patients. The
clinical presentation is in accordance with the genetic de-
fect that affects only the muscular isoform of the PiC cre-
ated by alternative tissue-speciﬁc splicing. It can be as-
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sumed that mutations of the PiC outside the regions af-
fected by alternative splicing would lead to a generalized
disorder in mitochondrial-energy metabolism and a mul-
tisystemic clinical presentation.
Deﬁciency of the mitochondrial PiC cannot be identi-
ﬁed by the analysis of the mitochondrial-energy metab-
olism in frozen tissue. Since the diagnosis of mitochon-
drial disorders is based on measurements of frozen tissue
in many laboratories, this kind of defect can easily be
missed. Therefore, at the moment, it is difﬁcult to estimate
the incidence of this novel disorder. We suggest that pa-
tients with clear clinical signs of a mitochondrial disorder
but normal activities of respiratory-chain enzymes be re-
evaluated. Functional investigation of intact mitochon-
dria should be performed to detect disorders of ATP syn-
thesis, including mitochondrial-PiC deﬁciency, and other
mitochondrial transport defects.
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